Several questions about SLE pathogenesis have continued to puzzle investigators over decades.A major question in the pathogenesis of SLE is the role of self-antigen. Early studies suggested that SLE ...

Background Abnormalities of type I interferon signaling and production can initiate lupus development. Disturbances of nucleic acid-sensing molecules triggered autoreactivity in lupus mouse models.

Background People with SLE (and their doctors) are concerned about the risk of COVID-19 infection, yet some patients still harbor concerns regarding vaccination. The first mRNA SARS-CoV-2 vaccines ...

Background Ultraviolet light (UV) is a known trigger of cutaneous lupus erythematosus (CLE) flares in systemic lupus erythematosus (SLE) patients, yet cell populations and mechanisms driving UV- ...

Results When comparing OT images of a total of 48 PIPs from healthy volunteers and 160 PIPs from SLE patients, an AUC of 0.79 is obtained with corresponding sensitivity and specificity of 77% and 71% ...

Background Lupus nephritis (LN) is a common and severe complication of systemic lupus erythematosus requiring renal biopsy to guide treatment decisions. Despite standard-of-care therapy, a third of ...

Background SLE is an inflammatory condition associated with hyperactivation of the immune system, with mounting evidence that imbalances in the gut microbiota communities are common. These imbalances ...

Background Pathologic inflammation is a major driver of kidney damage in lupus nephritis (LN), but the immune mechanisms of disease progression and risk factors for end organ damage are poorly ...

Objective It is still a matter of debate whether low-dose acetylsalicylic acid (LDASA) should be prescribed to all patients with SLE during pregnancy. This study aimed at investigating the impact of ...

Patients with antiphospholipid antibodies (aPL) are at increased risk for arterial or venous thrombosis. There is, however, significant heterogeneity among patients according to clinical and ...

Objective To confirm that metformin prevents flares in patients with SLE with low disease activity, we performed a post hoc analysis combining our previous two randomised trials.Methods Post hoc ...

Background The small molecule BI 705564 is a highly selective, covalent and potent inhibitor (B cell CD69 activation IC50=2.2 nM) of the Brutons tyrosine kinase (BTK). BTK plays a critical role in the ...